ABSTRACT Nytricx, Inc. (C Corp. registered in GA) is the recent recipient of a Phase II STTR NHLBI administered grant application (Award Number: 2R42HL149595-02A1, project period 05/01/2020 to 07/31/2025). The title of the funded application is “Ultra-low Fouling and Anti-infective and Anti- thrombotic Nitric Oxide Releasing Intravascular Catheters.” Indwelling vascular catheters are prone to two major medical complications: thrombosis (blood clots) and infection immediately after its insertion. Despite a crowded market and decades of research, a truly dual non- thrombogenic and antibacterial surface has yet to be commercialized. Nytricx has recently recruited and hired a US Citizen and minority candidate, Ms. Pravalika Irukulla, BS, MS in Biological Engineering for their UGA Innovation Gateway leased research space at 220 Riverbend Road, Room 027, Athens, GA 30602. Ms. Irukulla started her full-time employment with the Company on September 21, 2023 and her job title is Research Associate I. Her major responsibilities are to perform bench top fabrication of anti-infective Nitric Oxide (NO) releasing intravascular catheters, determine catheter stability and release kinetics of NO gas from various catheter polymers employed in loading of NO donors into intravascular catheters, determine the antimicrobial efficacy of NO-releasing intravascular catheters in vitro and in vivo, determine the anti-thrombotic efficacy of NO-releasing intravascular catheters in vivo, maintain the Company research laboratory in high operating fashion, and order and inventory all supplies required by the laboratory for the research work to be contemplated and completed.